SGS, a leading bio/pharmaceutical, analytical and bioanalytical contract solutions provider, has announced that it has invested in multiple highly sensitive and selective LC-MS/MS instruments at its Poitiers, France, laboratory, for the quantification of proteins and peptide therapeutics.
The two systems, which are now installed and validated, are a combination of the AB SCIEX 6500+ and Shimadzu X2 UPLC, which offers high specificity, a wide dynamic range, faster method development and the ability to quantify multiple proteins simultaneously.
LC-MS/MS techniques have a number of advantages compared with standard conventions for protein and peptide quantitation, which are based on ligand-binding assays (LBAs) such as the enzyme-linked immunosorbent assay (ELISA).
Assay development can often be time-consuming and expensive and, in addition, LBA results are often plagued by interferences and high background from antibody cross-reactivity.
“Mass spectrometry platforms have universal applicability, providing one technique for a large diversity of analytes,” commented Dr Walid Elbast, Director LC-MS at SGS Poitiers.
“All types of proteins and peptides can be quantified by LC/MS/MS without exception, and a wide diversity of other biomolecules such as lipids and carbohydrates can also be quantified, providing researchers with a highly sensitive, selective and flexible bioanalytical platform.”
With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly owned global network, present in North America, Europe and Asia, to deliver harmonised solutions to large pharmaceutical and biotechnology firms.
In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance and regulatory consultancy.